1. Signaling Pathways
  2. Cell Cycle/DNA Damage
    Epigenetics
  3. HDAC
  4. HDAC4 Isoform

HDAC4

 

HDAC4 Related Products (30):

Cat. No. Product Name Effect Purity
  • HY-15149
    Romidepsin
    Inhibitor 99.98%
    Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities.
  • HY-16026
    Ricolinostat
    Inhibitor 99.83%
    Ricolinostat (ACY-1215) is a potent and selective HDAC6 inhibitor, with an IC50 of 5 nM.
  • HY-10528
    Tasquinimod
    Modulator 99.86%
    Tasquinimod is an oral antiangiogenic agent, which has the potential for castration-resistant prostate cancer treatment.
  • HY-18361
    TMP195
    Inhibitor 99.19%
    TMP195 is a selective class IIa histone deacetylase (HDAC) inhibitor with an IC50 of 300 nM.
  • HY-18360
    TMP269
    Inhibitor 98.23%
    TMP269 is a novel and selective class IIa histone deacetylase (HDAC) inhibitor with IC50s of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.
  • HY-146678
    HDAC6-IN-5
    Inhibitor
    HDAC6-IN-5 (compound 11b) is a potent and BBB-penetrated HDAC6 inhibitor, with an IC50 of 0.025 μM.
  • HY-150109
    Purinostat mesylate
    Inhibitor
    Purinostat mesylate is a selective inhibitor of HDAC.
  • HY-146679
    HDAC6-IN-6
    Inhibitor
    HDAC6-IN-6 (compound 6a) is a potent and BBB-penetrated HDAC6 inhibitor, with an IC50 of 0.025 μM.
  • HY-13522
    Fimepinostat
    Inhibitor 99.95%
    Fimepinostat (CUDC-907) potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes with an IC50 of 19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10 , respectively.
  • HY-15433
    Quisinostat
    Inhibitor 98.28%
    Quisinostat (JNJ-26481585) is a potent, second-generation and orally active pan-HDAC inhibitor (HDACi), with IC50 values ranging from 0.11 nM to 0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11.
  • HY-13428
    Tubacin
    Inhibitor
    Tubacin is a potent and selective inhibitor of HDAC6, with an IC50 value of 4 nM and approximately 350-fold selectivity over HDAC1.
  • HY-10223
    CUDC-101
    Inhibitor 99.19%
    CUDC-101 is a potent inhibitor of HDAC, EGFR, and HER2 with IC50s of 4.4, 2.4, and 15.7 nM, respectively.
  • HY-13322
    Pracinostat
    Inhibitor 99.82%
    Pracinostat is a potent histone deacetylase (HDAC) inhibitor, with IC50s of 40-140 nM, used for cancer research.
  • HY-16699
    Nexturastat A
    Inhibitor 99.03%
    Nexturastat A is a potent HDAC6 inhibitor with an IC50 of 5 nM.
  • HY-14842B
    Givinostat hydrochloride monohydrate
    Inhibitor ≥98.0%
    Givinostat hydrochloride monohydrate (ITF-2357 hydrochloride monohydrate) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively.
  • HY-19350
    BML-210
    Inhibitor 98.06%
    BML-210 is a novel HDAC inhibitor, and its mechanism of action has not been characterized.
  • HY-115475
    SW-100
    Inhibitor 99.59%
    SW-100, a selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 of 2.3 nM, shows at least 1000-fold selectivity for HDAC6 relative to all other HDAC isozymes.
  • HY-119939
    CHDI-390576
    Inhibitor 99.42%
    CHDI-390576, a potent, cell permeable and CNS penetrant class IIa histone deacetylase (HDAC) inhibitor with IC50s of 54 nM, 60 nM, 31 nM, 50 nM for class IIa HDAC4, HDAC5, HDAC7, HDAC9, respectively, shows >500-fold selectivity over class I HDACs (1, 2, 3) and ~150-fold selectivity over HDAC8 and the class IIb HDAC6 isoform.
  • HY-12954
    PTACH
    Inhibitor 99.65%
    PTACH (NCH-51) is a potent HDAC inhibitor with IC50s of 48 nM, 32 nM, and 41 nM for HDAC1, HDAC4, and HDAC6, respectively.
  • HY-14842
    Givinostat
    Inhibitor
    Givinostat (ITF-2357) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively.